Literature DB >> 11140801

Assessment of deep vein thrombosis or pulmonary embolism by the combined use of clinical model and noninvasive diagnostic tests.

P S Wells1, D R Anderson, J Ginsberg.   

Abstract

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are relatively common diseases and are amenable to therapy but with a potentially fatal outcome if untreated. The diagnosis can be made in most patients with use of the noninvasive imaging tests, but limitations exist. The standard first choice of investigation in patients with suspected DVT is compression ultrasonography (CUS). As with all tests, there is a potential for false-positive and false-negative results. The latter are especially an issue for calf vein thrombi, and this in part has led to the concept of serial CUS testing of the proximal venous system and not imaging of the calf. The premise of the repeat (serial) CUS test is that only thrombi that extend to the proximal system are clinically relevant, and these thrombi will be detected during subsequent testing. However, despite the safety of the serial CUS testing concept, it is inconvenient and expensive. The standard first choice of investigation in patients with suspected PE, the ventilation-perfusion (V/Q) lung scan is nondiagnostic in most cases. In the past few years, the diagnostic process has improved because of the validation of clinical models that accurately categorize patients as having low (5%), moderate (20% to 30%), or high probability (>60%) for venous thromboembolic disease. Among the improvements this provides is the elimination of serial CUS testing if the ultrasound results are normal and the clinical probability is low in patients with suspected DVT. In patients with suspected PE in whom further testing is necessary, determination of clinical probability allows selection of invasive (angiography) or noninvasive testing (serial ultrasound) in patients with non-high-probability V/Q scans. The fibrin degradation product D-dimer has had a high negative predictive value; negative results with enzyme-linked immunosorbent assay (ELISA) tests effectively rule out DVT or PE. In addition, a negative result with less-sentive D-dimer testing and a low clinical probability excludes DVT or PE.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11140801     DOI: 10.1055/s-2000-13219

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  11 in total

1.  Residents case report: deep vein thrombosis in a high school baseball pitcher following ulnar collateral ligament (ucl) reconstruction.

Authors:  Joseph Hannon; Craig Garrison; John Conway
Journal:  Int J Sports Phys Ther       Date:  2013-08

2.  Série « Prévenir la thrombose »: Sensibiliser les professionnels de la santé à la thrombose liée au cancer.

Authors:  Julia A Bayadinova; Laurie A Sardo; Lynne Penton; Susan Jenkins
Journal:  Can Oncol Nurs J       Date:  2022-04-01

3.  'Spot the CLOT': Awareness of cancer-associated thrombosis in healthcare providers.

Authors:  Julia A Bayadinova; Laurie A Sardo; Lynne Penton; Susan Jenkins
Journal:  Can Oncol Nurs J       Date:  2022-04-01

4.  Evaluation of models to predict BRCA germline mutations.

Authors:  H H Kang; R Williams; J Leary; C Ringland; J Kirk; R Ward
Journal:  Br J Cancer       Date:  2006-10-09       Impact factor: 7.640

5.  Development of a pediatric-specific clinical probability tool for diagnosis of venous thromboembolism: a feasibility study.

Authors:  Bryce A Kerlin; Julie A Stephens; Mark J Hogan; William E Smoyer; Sarah H O'Brien
Journal:  Pediatr Res       Date:  2014-12-17       Impact factor: 3.756

Review 6.  Cardiopulmonary laboratory biomarkers in the evaluation of acute dyspnea.

Authors:  Natalie R Stokes; Brett W Dietz; Jackson J Liang
Journal:  Open Access Emerg Med       Date:  2016-05-17

7.  Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Institute/Food and Drug Administration guideline: results of a multicenter management study.

Authors:  Carlos Aguilar; Michelangelo Sartori; Armando D'Angelo; Christopher Kabrhel; James Groce; Emmanuel de Maistre; Suman M Wasan; Jeannine Kassis; John Lazarchick; Colin Kaide; Pascual Marco Vera; Jeffrey Kline; D Mark Courtney; Andrew Rubin; Melhem Sharafuddin; Gilles Pernod
Journal:  Blood Coagul Fibrinolysis       Date:  2018-09       Impact factor: 1.276

Review 8.  Blood Flow Restriction Exercise: Considerations of Methodology, Application, and Safety.

Authors:  Stephen D Patterson; Luke Hughes; Stuart Warmington; Jamie Burr; Brendan R Scott; Johnny Owens; Takashi Abe; Jakob L Nielsen; Cleiton Augusto Libardi; Gilberto Laurentino; Gabriel Rodrigues Neto; Christopher Brandner; Juan Martin-Hernandez; Jeremy Loenneke
Journal:  Front Physiol       Date:  2019-05-15       Impact factor: 4.566

Review 9.  Respiratory review of 2013: pulmonary thromboembolism.

Authors:  Hun Gyu Hwang; Sam Schulman
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-09-30

10.  Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study.

Authors:  Gilles Pernod; Haifeng Wu; Emmanuel de Maistre; John Lazarchick; Jeannine Kassis; Carlos Aguilar; Pascual M Vera; Gualtiero Palareti; Armando D'Angelo
Journal:  Blood Coagul Fibrinolysis       Date:  2017-04       Impact factor: 1.276

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.